BD-311

N/A

Report date: 2025/03/04 14:50:31

Base Information

Drug NameBD-311
Drug Alias NameBD311
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vector
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsDiabetic macular oedemaRetinal Vein OcclusionMacular Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai BDgene Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai BDgene Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetic macular oedemaRetinal Vein OcclusionMacular Degeneration
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A